Spruce Biosciences (SPRB) Appoints New Director Keli Walbert
SPRUCE BIOSCIENCES, INC.
Subscribe to track SPRB
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Spruce Biosciences (SPRB) Appoints New Director
Company: SPRUCE BIOSCIENCES, INC. (SPRB) Form: 3 | Filed: 2025-12-15 Significance: Low
Insider: Walbert Keli Relationship: Director
Transaction: • Type: Initial Statement of Ownership • Shares Transacted: 0 • Owned After: 0
Key Insight: A new director, Keli Walbert, has joined the board of Spruce Biosciences, reporting no initial beneficial ownership of company stock as of the event date.
Market Context: This is a standard corporate governance filing required for new insiders. It does not represent any insider trading activity.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: SPRUCE BIOSCIENCES, INC. (SPRB)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Keli Walbert has been appointed as a new director and has filed an initial statement of beneficial ownership indicating no holdings in the company.
- Market Impact: Neutral. This filing is a routine corporate governance disclosure.
Company Information
| Field | Value |
|---|---|
| Company | SPRUCE BIOSCIENCES, INC. |
| Ticker Symbol | SPRB |
| CIK | 0001683553 |
| Industry | PHARMACEUTICAL PREPARATIONS |
Insider Information
| Field | Value |
|---|---|
| Name | Walbert Keli |
| CIK | 0002051489 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
This Form 3 is an initial statement of beneficial ownership and does not report a transaction. The filing indicates that the new insider owned no securities of the company at the time of the report.
| Field | Value |
|---|---|
| Form Type | 3 |
| Event Date | 2025-12-11 |
| Shares Owned | 0 |
Financial Impact Assessment
Transaction Materiality
As no transaction occurred, a materiality assessment is not applicable. The filing's purpose is to establish the new director's initial ownership status, which is zero.
Impact Evaluation
- Market Cap Context: Spruce Biosciences is a small-cap company with a market capitalization of approximately $110 million. The appointment of a new director is a standard governance event.
- Ownership Concentration: The new director holds no stake in the company, so this filing does not change insider ownership concentration.
- Significance: The significance is low as this is a procedural filing. Market participants typically watch for subsequent Form 4 filings, which would disclose any future purchases or sales by the new director.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: A Form 3 filing, especially one reporting zero shares, is purely informational and does not provide any signal regarding insider sentiment or future company performance.
Volume & Sentiment
- Expected Volume Impact: Negligible. This type of filing does not typically influence trading volume.
- Sentiment Indicator: Neutral.
Key Takeaways
- New Director Appointed: Keli Walbert is a new director on the board of Spruce Biosciences.
- No Initial Stake: The director did not own any company stock at the time of their appointment.
- Informational Filing: This Form 3 serves as a baseline for any future transactions, which will be reported on Form 4.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.